Key Highlights

  • Picard Medical (NYSEAMERICAN:PMI) was down 3.41% in premarket trading on October 9, 2026 on a listed price of USD 9.68 and a Market Value of about USD 23 million, with a relative strength index of 72.3, an overbought reading.
  • The screener tags share issuance, but no offering or issuance announcement was found for October 8 or 9; the company said on August 19 it is evaluating additional financing opportunities.
  • Second-quarter 2026 Revenue rose 39% to about USD 3.0 million, gross Margin turned positive at about 20.9%, and net loss narrowed 16% to about USD 5.7 million, per the company release.
  • A 1-for-50 reverse split took effect on July 31, 2026, and NYSE American accepted the company's listing compliance plan in July, a sign the stock needed to lift its price.

What Moved Picard Medical Shares

Picard Medical (NYSEAMERICAN:PMI) was indicated down 3.41% in the October 9, 2026 premarket session on the screener, on a listed price of USD 9.68 and premarket Volume of 497 shares. The screener tags the catalyst as share issuance, but a search found no company release or filing about an offering or issuance dated October 8 or 9, so that label is unverified. The listed price is the October 8 close, when the shares rose 3.31%, and a relative strength index of 72.3 shows an overbought reading, which makes a pullback plausible, an inference. Trading has also been halted for Volatility several times in recent weeks, according to a data page.

Growth, Reverse Split and Funding Needs

Picard Medical makes the SynCardia total artificial heart for patients with advanced heart failure and is based in Tucson, Arizona. In the second quarter of 2026 revenue rose 39% to about USD 3.0 million, mainly from higher United States sales, and first-half revenue rose 50% to about USD 4.1 million. Gross margin was about 20.9% against a gross loss a year earlier. Net loss narrowed to about USD 5.7 million for the quarter but widened to about USD 13.3 million for the half. The company completed a 1-for-50 reverse split on July 31, leaving about 2.34 million shares, and said it is evaluating additional financing.

Risks and What to Watch

A company losing about USD 13.3 million in six months on revenue of USD 4.1 million will probably need to issue shares, and with only about 2.34 million shares outstanding, even a small offering can be large relative to the float. Picard Medical (NYSEAMERICAN:PMI) also depends on a single product line, regulatory approvals for new devices and a long development path for the Emperor total artificial heart. Its Leadership changed in June, when the chief executive stepped down. Investors should watch any offering announcement, cash disclosures, which the release did not provide, and listing compliance updates. A premarket decline on 497 shares can reverse at the open, so the figure is only a snapshot of one early session.

Where Things Stand

Picard Medical (NYSEAMERICAN:PMI) is down in premarket, but the screener's share issuance tag could not be verified, so the cause is unconfirmed. The verified backdrop is fast revenue growth from a small base, narrowing quarterly losses, a July reverse split and an explicit need for more financing. The balance of evidence is that a small, overbought stock is fading on thin volume while dilution risk remains. The next checkpoints are any financing announcement and the next quarterly report.